Johnson & Johnson Net Income/Loss 2010-2024 | JNJ
Johnson & Johnson annual/quarterly net income/loss history and growth rate from 2010 to 2024. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- Johnson & Johnson net income/loss for the quarter ending September 30, 2024 was $10.635B, a 65.81% decline year-over-year.
- Johnson & Johnson net income/loss for the twelve months ending September 30, 2024 was $56.984B, a 5.42% increase year-over-year.
- Johnson & Johnson annual net income/loss for 2023 was $35.153B, a 95.94% increase from 2022.
- Johnson & Johnson annual net income/loss for 2022 was $17.941B, a 14.07% decline from 2021.
- Johnson & Johnson annual net income/loss for 2021 was $20.878B, a 41.89% increase from 2020.
Johnson & Johnson Annual Net Income/Loss (Millions of US $) |
2023 |
$35,153 |
2022 |
$17,941 |
2021 |
$20,878 |
2020 |
$14,714 |
2019 |
$15,119 |
2018 |
$15,297 |
2017 |
$1,300 |
2016 |
$16,540 |
2015 |
$15,409 |
2014 |
$16,323 |
2013 |
$13,831 |
2012 |
$10,514 |
2011 |
$9,672 |
2010 |
$13,334 |
2009 |
$12,266 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Large Cap Pharmaceutical |
$347.829B |
$85.159B |
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|